Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Drug Administration Schedule Clear all
Completed Not applicable Interventional

Effect of Interleukin-2 on HIV Treatment Interruption

NCT00015704
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • San Jose, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 3 Interventional

Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)

NCT00002224
View directory record Official record
Conditions
HIV Infections
Interventions
Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2011 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Study of Itraconazole in Patients With Advanced HIV Infection

NCT00002370
View directory record Official record
Conditions
HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Not applicable Interventional

Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients

NCT00001131
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin, HAART
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Not applicable Interventional

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

NCT00002236
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:49 AM EDT
Not listed Phase 2 Interventional

Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV

NCT00017992
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/Ritonavir, Emtricitabine, Stavudine
Drug
Lead sponsor
Triangle Pharmaceuticals
Industry
Eligibility
3 Months to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Jacksonville, Florida • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1 Interventional

A Study of CI-1012 in HIV-Infected Patients

NCT00002196
View directory record Official record
Conditions
HIV Infections
Interventions
CI-1012
Drug
Lead sponsor
Parke-Davis
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
Palm Springs, California • San Francisco, California • Maitland, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:49 AM EDT
Suspended Phase 2 Interventional

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

NCT00002424
View directory record Official record
Conditions
HIV Infections
Interventions
L-756423, Indinavir sulfate, Lamivudine, Stavudine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
16
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Fort Myers, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Not applicable Interventional Results available

Long-term Behavior Change - 1

NCT00158197
View directory record Official record
Conditions
Amphetamine-related Disorders
Interventions
contingency management voucher
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Los Angeles, California • Rancho Cucamonga, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

NCT00006604
View directory record Official record
Conditions
HIV Infections
Interventions
ATV, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
91 Days to 21 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
32
States / cities
Birmingham, Alabama • Alhambra, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 4 Interventional

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

NCT00055120
View directory record Official record
Conditions
HIV Infections, AIDS-Related Opportunistic Infections
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Lopinavir/ritonavir, Stavudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
43
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 25, 2026, 10:49 AM EDT
Not listed Phase 1 Interventional

Post IVIG Medication in Children With Immune Thrombocytopenia

NCT04741139
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Acetaminophen and Diphenhydramine Only Product
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Month to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2022 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Tenofovir Disoproxil Fumarate (Tenofovir DF) Plus Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002450
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir disoproxil fumarate
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Not applicable Interventional Results available

Regimen Education and Messaging in Diabetes (REMinD)

NCT03185741
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Medication Adherence
Interventions
UMS Strategy, SMS Text Messaging
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
21 Years and older
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1 Interventional

A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women

NCT00000864
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 28 Days
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV

NCT00011011
View directory record Official record
Conditions
HIV Infections
Interventions
ALVAC(2)120(B,MN)GNP (vCP1452)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 25, 2026, 10:49 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer

NCT07258407
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostatic Cancer
Interventions
TD001
Drug
Lead sponsor
T.O.A.D. Oncology SA
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults

NCT00069030
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 25, 2026, 10:49 AM EDT
Not yet recruiting Phase 2 Interventional

FG001 Near-Infrared Fluorescence Imaging During Tumor Resection in Newly Diagnosed High-Grade Glioma

NCT07609472
View directory record Official record
Conditions
High-Grade Glioma (WHO III-IV)
Interventions
FG001
Drug
Lead sponsor
FluoGuide A/S
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Miami, Florida • Lebanon, New Hampshire • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1 Interventional

Zidovudine and Lamivudine Given Once Versus Twice Daily

NCT00014014
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 24 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
19
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2013 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 2 Interventional

Ondansetron for the Treatment of Cocaine Dependence - 1

NCT00033085
View directory record Official record
Conditions
Cocaine-Related Disorders, Drug Administration Schedule
Interventions
Ondansetron
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 25, 2026, 10:49 AM EDT
Completed Phase 1 Interventional

Blood Levels of Abacavir After One Dose in HIV-Infected Children and Adolescents

NCT00011479
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
9 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 25, 2026, 10:49 AM EDT
Not listed Phase 3 Interventional

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

NCT00004981
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Lamivudine/Zidovudine, Abacavir sulfate
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 25, 2026, 10:49 AM EDT